It was found that all these clinical trials were multi-centric and conducted in and after 2015 across different parts of the World, enrolling type 2 DM patients with varied baseline characteristics in terms of age, BMI, sex, glomerular filtration rate, history of existing renal diseases, etc. In spite of these differences, the SGLT2 drugs were found to be beneficial by significantly reducing all-cause mortality, mortality due to CV causes, and risk of major CV events. Here, SLC5A2 is linked to kidney disorder.